Breaking Down the Components: SCHV May Hold a Value of $32
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 23 2025
0mins
Source: NASDAQ.COM
ETF Performance Analysis: The Schwab U.S. Large-Cap Value ETF (SCHV) has an implied analyst target price of $32.37, indicating an 11.27% upside from its recent trading price of $29.09.
Notable Holdings with Upside: Key underlying holdings of SCHV, such as Jazz Pharmaceuticals (JAZZ), Corplay Inc (CPAY), and Masimo Corp (MASI), show significant potential upside based on analyst target prices, with JAZZ at 34.91% higher, CPAY at 32.98%, and MASI at 27.40%.
Analyst Target Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets could lead to future downgrades if they do not align with market realities.
Investor Research Recommendation: Investors are encouraged to conduct further research to assess the validity of analyst targets in light of recent company and industry developments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MASI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MASI
Wall Street analysts forecast MASI stock price to rise
6 Analyst Rating
4 Buy
2 Hold
0 Sell
Moderate Buy
Current: 179.950
Low
162.00
Averages
188.40
High
210.00
Current: 179.950
Low
162.00
Averages
188.40
High
210.00
About MASI
Masimo Corporation is a global medical technology company that develops and produces a wide range of monitoring technologies, including measurements, sensors, patient monitors, automation and connectivity solutions. The Company’s healthcare products and patient monitoring solutions generally incorporate a monitor or circuit board, proprietary single-patient use or reusable sensors, software and/or cables. It primarily sells its healthcare products to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, long-term care facilities. Its measurement technologies include Measure-through Motion and Low Perfusion pulse oximetry, known as Masimo Signal Extraction Technology (SET) pulse oximetry, and advanced rainbow Pulse CO-Oximetry parameters such as noninvasive hemoglobin (SpHb), alongside many other modalities, including brain function monitoring, hemodynamic monitoring, regional oximetry, capnography and gas monitoring, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sirius XM to Replace Masimo in S&P MidCap 400 Index
- Acquisition Impact: Danaher Corp. is set to acquire Masimo for $180 per share, valuing the deal at approximately $9.9 billion including debt, with completion expected in the second half of 2026, allowing Masimo to operate as a standalone business within Danaher's Diagnostics segment.
- Index Change: S&P Dow Jones Indices announced that Sirius XM will replace Masimo in the S&P MidCap 400 effective June 11, which is anticipated to trigger buying from index-tracking funds and ETFs, further enhancing Sirius XM's market performance.
- Market Reaction: Sirius XM's market capitalization is around $9 billion, and its shares rose 5% in after-hours trading on Monday, reflecting positive market sentiment regarding its inclusion in the mid-cap index, despite retail investor sentiment remaining bearish.
- Year-to-Date Performance: Sirius XM's stock has gained 34% this year, driven by Berkshire Hathaway's increasing stake and a significant audio advertising partnership with YouTube, indicating the company's ongoing growth potential in the audio entertainment sector.
See More
SiriusXM to Replace Masimo in S&P MidCap 400 Index
- Index Component Change: SiriusXM Holdings (SIRI) will replace Masimo (MASI) in the S&P MidCap 400 Index prior to market open, enhancing SiriusXM's market visibility and liquidity, potentially attracting more investor interest.
- Market Impact Analysis: As part of the mid-cap index, SiriusXM's inclusion is expected to increase its trading volume, which may drive up its stock price, reflecting market confidence in its future growth potential.
- Investor Attention Boost: Changes in S&P MidCap 400 Index components typically garner significant investor attention, and SiriusXM's replacement may prompt fund managers to reassess their portfolios, thereby increasing investment in the company.
- Strategic Significance: This replacement not only signifies an elevation of SiriusXM's market position but may also provide more opportunities for future capital operations and business expansion, further solidifying its leadership in the audio entertainment industry.
See More
Danaher Anticipates 6% Revenue Growth by 2027
- Revenue Growth Outlook: Danaher anticipates approximately 6% revenue growth by 2027, primarily driven by a rebound in bioprocess demand, indicating the company's market potential and signs of recovery in the biotech sector.
- Market Demand Recovery: As the bioprocessing industry rebounds, demand for Danaher's products and services is expected to increase, providing new revenue streams and enhancing its competitive position in the market.
- Strategic Adjustments: The company may adjust its product portfolio in response to changing market demands, thereby improving overall business performance and profitability to better meet customer needs.
- Long-Term Perspective: This growth outlook reflects Danaher's confidence in future markets, suggesting that the company's investments and innovations in biotechnology will continue to drive sustainable development.
See More
DANAHER CORP PLANS TO UTILIZE NET PROCEEDS FOR PARTIAL FUNDING OF MASIMO ACQUISITION
- Danaher Corp's Financial Strategy: Danaher Corp plans to utilize proceeds from a recent transaction to partially fund the acquisition of Masimo.
- Acquisition Details: The acquisition of Masimo is part of Danaher's strategy to expand its portfolio in the healthcare sector.
See More
Apple Wins Patent Dispute Against Masimo
- Patent Dispute Outcome: The U.S. International Trade Commission ruled in favor of Apple (AAPL) in its patent dispute with medical device maker Masimo (MASI), rejecting Masimo's request for an import ban on certain Apple Watch models, demonstrating Apple's legal strength in technology competition.
- Legal Battle History: Since 2021, Masimo has accused Apple of poaching key engineers and stealing its developed pulse oximetry technology, and despite launching multiple lawsuits over six years, nearly all claims have been dismissed, reflecting Apple's robust legal defense capabilities.
- Market Reaction: At the time of this announcement, retail sentiment around MASI and AAPL stocks remained in the 'bullish' territory, with MASI stock gaining 17% over the past 12 months and AAPL stock rising 37%, indicating strong market confidence in Apple.
- Future Outlook: Although Masimo can appeal the decision to the U.S. Court of Appeals for the Federal Circuit, Apple's victory may further solidify its leadership in the smartwatch market and reduce future legal risks.
See More
Masimo Secures $100M Patient Monitoring Contract
- Significant Contract Value: Masimo has secured a maximum fixed-price contract worth approximately $100 million for patient monitoring and capital equipment, reflecting strong demand and market confidence in the medical device sector.
- Extended Contract Duration: This award exercises the five-year option period under the existing five-year base contract, with the ordering period running through April 19, 2031, ensuring a stable revenue stream for Masimo in the coming years.
- Broad Customer Base: The contract supports customers across the Army, Navy, Air Force, Marine Corps, and federal civilian agencies, highlighting Masimo's critical position and influence in the defense medical equipment market.
- Clear Funding Source: The contract is funded through FY2026–2031 defense working capital funds, demonstrating the government's ongoing investment and trust in Masimo's products, further solidifying the company's market position.
See More
Sirius XM to Replace Masimo in S&P MidCap 400 Index
- Acquisition Impact: Danaher Corp. is set to acquire Masimo for $180 per share, valuing the deal at approximately $9.9 billion including debt, with completion expected in the second half of 2026, allowing Masimo to operate as a standalone business within Danaher's Diagnostics segment.
- Index Change: S&P Dow Jones Indices announced that Sirius XM will replace Masimo in the S&P MidCap 400 effective June 11, which is anticipated to trigger buying from index-tracking funds and ETFs, further enhancing Sirius XM's market performance.
- Market Reaction: Sirius XM's market capitalization is around $9 billion, and its shares rose 5% in after-hours trading on Monday, reflecting positive market sentiment regarding its inclusion in the mid-cap index, despite retail investor sentiment remaining bearish.
- Year-to-Date Performance: Sirius XM's stock has gained 34% this year, driven by Berkshire Hathaway's increasing stake and a significant audio advertising partnership with YouTube, indicating the company's ongoing growth potential in the audio entertainment sector.
See More
SiriusXM to Replace Masimo in S&P MidCap 400 Index
- Index Component Change: SiriusXM Holdings (SIRI) will replace Masimo (MASI) in the S&P MidCap 400 Index prior to market open, enhancing SiriusXM's market visibility and liquidity, potentially attracting more investor interest.
- Market Impact Analysis: As part of the mid-cap index, SiriusXM's inclusion is expected to increase its trading volume, which may drive up its stock price, reflecting market confidence in its future growth potential.
- Investor Attention Boost: Changes in S&P MidCap 400 Index components typically garner significant investor attention, and SiriusXM's replacement may prompt fund managers to reassess their portfolios, thereby increasing investment in the company.
- Strategic Significance: This replacement not only signifies an elevation of SiriusXM's market position but may also provide more opportunities for future capital operations and business expansion, further solidifying its leadership in the audio entertainment industry.
See More
Danaher Anticipates 6% Revenue Growth by 2027
- Revenue Growth Outlook: Danaher anticipates approximately 6% revenue growth by 2027, primarily driven by a rebound in bioprocess demand, indicating the company's market potential and signs of recovery in the biotech sector.
- Market Demand Recovery: As the bioprocessing industry rebounds, demand for Danaher's products and services is expected to increase, providing new revenue streams and enhancing its competitive position in the market.
- Strategic Adjustments: The company may adjust its product portfolio in response to changing market demands, thereby improving overall business performance and profitability to better meet customer needs.
- Long-Term Perspective: This growth outlook reflects Danaher's confidence in future markets, suggesting that the company's investments and innovations in biotechnology will continue to drive sustainable development.
See More
DANAHER CORP PLANS TO UTILIZE NET PROCEEDS FOR PARTIAL FUNDING OF MASIMO ACQUISITION
- Danaher Corp's Financial Strategy: Danaher Corp plans to utilize proceeds from a recent transaction to partially fund the acquisition of Masimo.
- Acquisition Details: The acquisition of Masimo is part of Danaher's strategy to expand its portfolio in the healthcare sector.
See More
Apple Wins Patent Dispute Against Masimo
- Patent Dispute Outcome: The U.S. International Trade Commission ruled in favor of Apple (AAPL) in its patent dispute with medical device maker Masimo (MASI), rejecting Masimo's request for an import ban on certain Apple Watch models, demonstrating Apple's legal strength in technology competition.
- Legal Battle History: Since 2021, Masimo has accused Apple of poaching key engineers and stealing its developed pulse oximetry technology, and despite launching multiple lawsuits over six years, nearly all claims have been dismissed, reflecting Apple's robust legal defense capabilities.
- Market Reaction: At the time of this announcement, retail sentiment around MASI and AAPL stocks remained in the 'bullish' territory, with MASI stock gaining 17% over the past 12 months and AAPL stock rising 37%, indicating strong market confidence in Apple.
- Future Outlook: Although Masimo can appeal the decision to the U.S. Court of Appeals for the Federal Circuit, Apple's victory may further solidify its leadership in the smartwatch market and reduce future legal risks.
See More
Masimo Secures $100M Patient Monitoring Contract
- Significant Contract Value: Masimo has secured a maximum fixed-price contract worth approximately $100 million for patient monitoring and capital equipment, reflecting strong demand and market confidence in the medical device sector.
- Extended Contract Duration: This award exercises the five-year option period under the existing five-year base contract, with the ordering period running through April 19, 2031, ensuring a stable revenue stream for Masimo in the coming years.
- Broad Customer Base: The contract supports customers across the Army, Navy, Air Force, Marine Corps, and federal civilian agencies, highlighting Masimo's critical position and influence in the defense medical equipment market.
- Clear Funding Source: The contract is funded through FY2026–2031 defense working capital funds, demonstrating the government's ongoing investment and trust in Masimo's products, further solidifying the company's market position.
See More
